Non-Small Cell Lung Cancer (NSCLC) - Metastatic

KNIGHT CANCER Institute
OHSU

CROSS-DISEASE TRIALS:

- IRB# 18084 S1609 (DART)
- IRB# 19992 MATCH: Molecular Analysis for Therapy Choice (MATCH)
- IRB# 21325: RGX-104

Recurrent or Metastatic (IIIB, IV)

1st line

Squamous

- IRB# 21821 CodeBreak 101: A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN Sotorasib) in Combination With AMG 404 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation

Non-squamous

- IRB# 21821 CodeBreak 101: A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN Sotorasib) in Combination With AMG 404 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation
- IRB# 21886 KEAPSAKE: A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous NSCLC

2nd/3rd Line

- IRB# 21821 CodeBreak 101: A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN Sotorasib) in Combination With AMG 404 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation
- IRB# 22772 S1900E: A Phase II Study of AMG 510 in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
- IRB# 21770 EA5191: A Randomized Phase II Trial of Cabozantinib and Cabozantinib plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated NonSquamous NSCLC
- IRB# 21589 S1900B: A PHASE II STUDY OF SELPERCATINIB (LOXO-292) IN PATIENTS WITH RET FUSION POSITIVE STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER (LUNG-MAP SUBSTUDY)

Key

- Open for Enrollment
- In Development
- Enrollment on Hold

3.1.2021

http://www.ohsu.edu/research/rda/so/knight.php